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SUMMARY
Drug development for paediatric applications entails a number of challenges, such as the wide age spectrum covered – from
birth to adolescence – and developmental changes in physiology during biological maturation that inﬂuence the eﬃcacy and
toxicity of drugs. Safe and eﬃcacious antiparasitic drugs for children are of pivotal importance given the large proportion of
burden attributable to parasitic diseases in this age group, and growing eﬀorts to administer, as widely as possible,
antiparasitic drugs to at-risk populations, such as infants and school-aged children, often without prior diagnosis. The
purpose of this review is to investigate whether antiparasitic drugs have been adequately studied for use in paediatrics. We
approached this issue through a systematic review using PubMed and the Cochrane Central Register of Trials covering a
period of 10 years and 8 months until the end of August 2010 to identify trials that investigated eﬃcacy, safety and
pharmacokinetic (PK) parameters of antiparasitic drugs for paediatrics. Overall, 269 clinical drug trials and 17 PK studies
met our inclusion criteria. Antimalarial drugs were the most commonly studied medicines (82·6%). Most trials were carried
out in Africa and children aged 2–11 years were the age group most often investigated. Additionally, we critically examined
available drug formulations for anthelminthics and identiﬁed a number of shortcomings that are discussed. Finally, we shed
new light on current proposals to expand ‘preventive chemotherapy’ to preschool-aged children and emphasise that new
research, including risk-beneﬁt analyses, are needed before such a strategy can be adopted more widely.
Key words: Antiparasitic drugs, antimalarials, anthelminthics, preventive chemotherapy, paediatrics, infants, children,
adolescence, systematic review, drug formulation.
INTRODUCTION
Drug development for the paediatric population is
a challenging endeavour, since a wide age spectrum
from birth to adolescence is covered. A useful
stratiﬁcation of the paediatric population is the one
proposed by the World Health Organization (WHO)
using the following ﬁve classes: (1) preterm newborn
infants; (2) term newborn infants (0 to 28 days);
(3) infants and toddlers (>28 days to 23 months);
(4) children (2 to 11 years); and (5) adolescents
(12 to 16–18 years) (WHO, 2007a). Importantly, the
developmental changes in physiology during bio-
logical maturation from newborns to adolescence
inﬂuence the eﬃcacy and toxicity of drugs. Indeed
absorption, distribution, metabolism, excretion and
toxicity (ADMET; see Glossary) are all age depen-
dent. Textbooks and detailed reviews are available
that summarise key factors responsible for diﬀerences
in drug disposition between paediatric and adult
population such as proportions of body fat, pro-
tein, extracellular water, organ size, membrane
permeability, plasma proteins, enzymes, glomerular
ﬁltration or tubular secretion (Strolin Benedetti et al.
2005; Rakhmanina and van den Anker, 2009). For
example, body water is decreased from 80% in
newborns to 60% in 5-month-old infants (WHO,
2007a). Moreover, absorption, stability and ionis-
ation of drugs depend on gastric pH, which is age-
dependent. In the neonatal period an elevated pH is
observed (i.e. the pH is neutral rather than acidic as in
adults), which explains that, in younger age groups,
a greater bioavailability of acid-labile compounds
occurs (e.g. penicillin) (Kearns et al. 2003).
In view of the aforementioned issues it is not
surprising that the need for age-appropriate pharma-
cotherapy was already recognised more than 100
years ago (Kearns et al. 2003). The International
Conference on Harmonisation of Technical Require-
ments for the Registration of Pharmaceuticals for
Human Use (ICH-E-11) states that “Paediatric
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patients should be given medicines that have been
appropriately evaluated for their use” (http://www.
fda.gov). We pose the question whether antiparasitic
drugs have been adequately evaluated prior to wider
application in paediatric populations. Indeed, ad-
dressing this question served as the main motivation
for the current paper, which forms part of a special
issue of Parasitology pertaining to “Progress in Pae-
diatric Parasitology” (see Stothard and Booth edi-
torial in this special issue).
We ﬁrst provide a short historical background on
paediatric drug development and highlight practical,
ethical and economic issues. We then juxtapose the
latest United Nations (UN) population ﬁgures
and disease burden estimates in the lowest income
countries. To strengthen the current evidence-base of
antiparasitic drugs in the paediatric population, we
performed a systematic review using two readily
available electronic databases. We examined the type
of drugs investigated, the age of the study partici-
pants and performed a temporal and geographical
analysis of studies meeting our inclusion criteria.
Paediatric pharmacokinetic (PK) studies were also
examined.With an emphasis on anthelminthic drugs,
we critically reviewed available drug formulations.
Finally, in the current era of ‘preventive (anthel-
minthic) chemotherapy’ (see Glossary), that is the
regular administration of antiparasitic drugs to entire
at-risk populations (WHO, 2006, 2010a), we discuss
implications for control programmes that aim at
including also preschool-aged children.
PAEDIATRIC DRUG DEVELOPMENT
Regulatory, ethical, commercial and economic issues
Regulatory eﬀorts to protect children from harm-
ful medications began in the mid-20th century, in
response to serious adverse events, such as limb
malformations caused by thalidomide (Barsch and
Otte, 2010). Indeed, thalidomide (Contergan®),
which had been used as a treatment for recurring
morning sickness in pregnant women during the
1950s and the early 1960s, caused peripheral neuritis
and malformations, e.g. phocomelia, in babies of
mothers who had taken thalidomide over the course
of their pregnancies (Stötter, 2007; Barsch and Otte,
2010). Once the evidence of these serious adverse
events of thalidomide had been established through
case-control studies, the medication was withdrawn
from the market (Mellin and Katzenstein, 1962).
As a consequence, many drugs received marketing
authorisation for use in adults only. However, an
increase in oﬀ-label use (see Glossary) was sub-
sequently observed, amounting to 80% in paediatric
patients (Pandolﬁni and Bonati, 2005; Stötter, 2007).
Bearing the aforementioned dilemmas in mind,
over the past two decades, regulations have been
enacted upon and incentives created; ﬁrst in the US
(e.g. Food and Drug Administration Modernization
Act (FDAMA) instigated in 1998 and Best Pharma-
ceuticals for Children Act (BPCA) put forth in 2002;
see Glossary) and, second by a number of EU pae-
diatric guidelines (Rose, 2009). The purpose of these
regulations was to improve paediatric drug develop-
ment, particularly in terms of safety (Schachter and
Ramoni, 2007; Macleod, 2010). It is clear that these
initiatives and regulations have changed the land-
scape for paediatric drug development. For example,
there are recent signs of enhanced research activities
going hand-in-hand with clinical trials on the eﬃcacy
and safety of drugs in children including PK studies
and the development of drug formulations that are
suitable for the paediatric population (Macleod,
2010).
Nonetheless, there are a number of challenges
regarding clinical trials in children. Ethical issues
include the complexity to obtain written informed
consent from parents and legal guardians, as well as
assents from participating children (Kuepfer and
Burri, 2009). Furthermore, the level of invasiveness
should be kept as little as possible, and hence the
number of blood samples and the amount of blood
taken in PK studies should be minimised (Howie,
2011). Scientiﬁc issues comprise, for example, the
necessity to stratify the patient population into dif-
ferent age groups or the need to develop microassays
to analyse small amounts of biological samples that
are typically obtained from paediatric populations
(Conroy et al. 2000; WHO, 2007a; Choonara, 2009).
Finally, there are commercial and economic issues
as the market for paediatric medicines is small com-
pared to the adult population (estimated to be less
than 10% of the total prescription drug market
(Milne, 2009)), and hence lacks attractiveness for
the international pharmaceutical industry. While
blockbusters mainly address highly prevalent chronic
diseases, children often experience acute illnesses,
and the chronic conditions that do exist in the pae-
diatric population are mostly rare disorders (WHO,
2007b; Milne and Bruss, 2008).
PAEDIATRIC DRUG DEVELOPMENT,
DEMOGRAPHY AND DISEASE BURDEN
In the US, since the FDAMA institutionalised an
incentive of a 6-monthpatent extension for previously
approved drugs in July 1998, a total of 173 drugs were
granted paediatric exclusivity (http://www.fda.gov/
downloads/Drugs/DevelopmentApprovalProcess/
DevelopmentResources/UCM223058.pdf). These
developments, it was claimed, showed the achieve-
ments made by FDAMA for the paediatric popu-
lation. However, it should be noted that most of these
patent extensions were for drugs targeting the central
nervous system (CNS) (e.g. anti-depressants), cardi-
ovascular system (e.g. ACE inhibitors), alimentary
tract and metabolism (e.g. anti-diabetic drugs) and
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anti-infectives (e.g. antibiotics). Indeed, a deeper
analysis revealed a major discrepancy between drugs
granted exclusivity and those frequently used by
children (e.g. respiratory drugs, dermatologicals and
anti-infectives) (Boots et al. 2007). Hence, the real
needs in paediatric drug development and use have
not been addressed by exclusivity rights granted by
FDAMA. In contrast they were primarily driven by
the adult drug market (Boots et al. 2007).
Those drugs that are currently available and are
essential for children must be prioritised for paedia-
tric development. Indeed, there is growing recog-
nition that among essential medicines, issues of
safety, access and formulations for the paediatric
population are of pressing global public health
relevance. This can be further underscored by
juxtaposing population ﬁgures put forth by the UN
(United Nations, 2009). In 2010, an estimated 2·47
billion were newborns, infants, children and ado-
lescents below the age of 19 years. The paediatric
population, therefore, currently accounts for more
than a third (35·7%) of the world’s population.
Meanwhile, it has been estimated that 432·5 million
children and adolescents currently live in the least
developed countries, which comprise 49 countries, of
which 33 are in Africa, 10 in Asia, ﬁve in Oceania and
one in Latin America and the Caribbean. Compared
to the total population in these 49 countries (i.e. 854
million), the paediatric population therefore accounts
for more than 50% (United Nations, 2009).
It is encouraging to note that new campaigns have
been launched with the goal to expedite paediatric
drug development. For example, “Make medicines
child size” is a global initiative launched inDecember
2007 under the leadership of WHO in order “to raise
awareness and accelerate action to address the need
for improved availability and access to safe child-
speciﬁc medicines for all children under 12” (http://
www.who.int/childmedicines/en/).Highprioritythe-
rapeutic areas include respiratory diseases as well as
parasitic and infectious diseases. The importance of
the latter group of diseases must be emphasised,
which is clear when one examines global burden of
disease estimates. In 2004, for example, children aged
below 14 years experienced the loss of 548·3 million
disability-adjusted life years (DALYs; see Glossary).
Three-quarter of this burden (409·8 million DALYs)
occurred among children from low-income countries.
Infectious and parasitic diseases were responsible
for more than 300 million DALYs, with 79% of
this burden concentrated in low-income countries,
disproportionally shared by children younger than
14 years (58%) (WHO, 2008a). The proportion of
disease burden attributable to infectious and parasitic
diseases in children in low-income countries was 38%
(154·3 million DALYs) (WHO, 2008a). Moreover,
infectious diseases are a leading cause of death in
children younger than 5 years, particularly in low-
income countries. The latest estimates for the year
2008 suggest that among the 8·80 million deaths in
children under the age of 5 years, two-third (68% or
5·97 million deaths) were due to infectious diseases,
the three most important of which were pneumonia
(1·56 million deaths), diarrhoea (1·34 million deaths)
and malaria (732,000 deaths) (Black et al. 2010).
Of note, intestinal parasites are responsible for
reductions in appetite, absorption, digestion and
increasing intestinal nutrient losses (Lunn and
Northrop-Clewes, 1993), and hence might contrib-
ute to undernutrition, which is the underlying cause
of a third of deaths in children younger than 5 years
(Black et al. 2010).
CLINICAL TRIALS WITH ANTIPARASITIC
DRUGS FOR PAEDIATRICS
Search strategy and selection criteria of a
systematic review
We were interested in clinical trials involving anti-
parasitic drugs in the paediatric population, as well
as PK studies, covering a period of 10 years and
8 months until the end of August 2010. Previous
articles highlighted the paucity of paediatric clinical
trials involving children in the developing world
(Sammons and Choonara, 2005; Nor Aripin et al.
2010a,b). For example, in 2007, only one out of four
trials were carried out in developing countries (Nor
Aripin et al. 2010b). Between 1996 and 2002, a total of
99 trials carried out in the developing world were
identiﬁed with a speciﬁc focus on antiparasitic and
anti-infective drugs. However, no details were pre-
sented on the type of medication studied or age group
involved (Nor Aripin et al. 2010a).
We performed a systematic review on PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) and the
Cochrane Central Register of Controlled Clinical
Trials (http://onlinelibrary.wiley.com/o/cochrane/
cochrane_clcentral_articles_fs.html). In order to
maximise sensitivity and speciﬁcity (Kastner et al.
2006), we used the following age-speciﬁc MeSH
terms: ‘child’, ‘adolescent’ or ‘infant’, in combination
with ‘clinical trial’ and ‘antiparasitic agent’. For the
search on PK studies, the same age-speciﬁc MeSH
terms were employed, but in combination with
‘pharmacokinetics’. Our searches were temporally
restricted (from 2000 to the end of August 2010),
while there was no language restriction. Abstracts of
the retrieved publications were analysed, adhering
to a standard protocol developed by the authors.
Studies had to pass the following inclusion criteria:
(1) study population of children or adolescents
(age:418 years); (2) trials investigating drug eﬃcacy
(e.g. no vaccination or supplements); and (3) study
performed on any parasitic disease. The following
information was retrieved from each study that
met our inclusion criteria: (i) year of publication;
(ii) parasite studied; (iii) study setting and country;
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(iv) sample size; (v) age and age group of study
population; (vi) methodological quality of trial; and
(vii) type of medication used (e.g. substance, prep-
aration and Anatomical Therapeutical Chemical
(ATC) classiﬁcation system; see Glossary).
Number of studies identiﬁed and age groups
A total of 1025 articles were identiﬁed. Based on the
abstracts 756 studies were excluded and full-text
copies were obtained from 269 articles. The three
main reasons for exclusion were: (1) study population
consisting of children and adult patients (44%); (2)
entire study population aged 18 years and above
(24%); and (3) trials investigating diagnostic tests or
focusing on health management issues (13%).
Additional exclusion criteria are summarised in
Fig. 1.
In four out of ﬁve trials (80%) both infants and
children (113 trials) or children only (102 trials) were
included. The remaining 20% of the trials involved
the following age classes: (1) children and adolescents
(34 trials); (2) infants (15 trials); (3) infants, children
and adolescents (four trials); and (4) adolescents
(one trial). More than 90% of the trials enrolled
children (93·7%), while only 39 trials included
adolescents. The number of participants per trial
ranged from 10 to 4906. One third of all trials
recruited between 101 and 250 participants. Table 1
shows the frequency of trials, stratiﬁed by diﬀerent
sample sizes.
Outcomes from temporal and geographical analyses
Our temporal analysis revealed that the number of
paediatric drug trials steadily increased between 2000
(only two trials) and 2004 (37 trials), decreased in
the following 2 years (25 and 23 studies in 2005 and
2006, respectively), and subsequently varied between
27 and 36 per year. In 2010, until the end of August
2010, a total of eight trials were identiﬁed for
antiparasitic drugs in paediatrics (Fig. 2).
The studies examined were carried out in 61
countries. More than a third of the trials (38·7%)
were conducted in only ﬁve countries: Thailand
(24 trials), Nigeria (21 trials), United Republic of
57 abstracts 
identified on 
paediatric PK 
trials Excluded (n=40) 
 Adults (n=29) 
 Mixed age (n=10) 
 No drug supplement (e.g. vaccines)  (n=1) 
1025 abstracts 
identified on 
paediatric clinical 
trials
269 studies 
included in 
analyses 
17 studies 
included in 
analyses 
Excluded (n=756) 
 Mixed age (n=330) 
 Adults (n=180) 
 Health management, diagnostics (n=98) 
 Lab value (e.g. haematocrit) (n=42) 
 Drug resistance, mutation (n=38) 
 No drug (e.g. vaccines) (n=38) 
 No clinical trial (n=20) 
 No parasitic disease (n=10) 
Fig. 1. Flow chart of study selection for systematic review of clinical trials and PK studies with antiparasitic drugs in
children covering a period of 10 years and 8 months until the end of August 2010.
Table 1. Number of paediatric patients involved
in clinical drug trials and pharmacokinetic (PK)
studies identiﬁed through a systematic review
covering a 10-year period until the end of
August 2010
Sample size (n)
Clinical drug
trials PK studies
No. % No. %
450 32 11·9 11 64·7
51–100 40 14·9 3 17·6
101–250 89 33·1 2 11·8
251–500 48 17·8 0 0
501–1000 32 11·9 1 5·9
1001–2500 26 9·7 0 0
2501–5000 2 0·7 0 0
Total 269 100 17 100
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2
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29
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8
Fig. 2. Temporal analysis of paediatric drug trials
identiﬁed through a systematic review covering a 10-year
period until August 2010. (* indicates that in 2010 only
the ﬁrst 8 months were analysed).
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Tanzania (21 trials), Uganda (20 trials) and Ghana
(18 trials). Interestingly, almost three-quarter of
the trials were implemented in Africa (72·7%).
The respective percentage of trials carried out in
Asia, South America, North America, Australia and
Europe was 16·8%, 3·6%, 3·3%, 2·0% and 1·6%,
respectively (Fig. 3).
Drugs investigated
Ninety-three percent of the drug trials that we
identiﬁed through our systematic review investigated
antiparasitic medications. The remainder of the
studies (7%) examined drugs of the following ATC
classes: alimentary tract and metabolism, blood and
blood forming organs, dermatologicals, systemic
hormonal preparations, anti-infectives for systemic
use, antineoplastic and immunomodulating agents,
musculo-skeletal system, CNS and respiratory sys-
tem. Less than a third (29%) of all included studies
were classiﬁed as randomised controlled trials.
Fig. 4 shows that most of the antiparasitic drugs
studied were antimalarials (82·6%), followed by
therapies for gastrointestinal nematodes (9·8%),
amoebiasis and other intestinal protozoal infections
(3·7%), schistosomiasis (2·9%) and agents against
leishmaniasis and trypanosomiasis (1·0%). A closer
inspection of the drugs studied showed that sulpha-
doxine-pyrimethamine (SP) was the most frequently
trialled medication (20% of all studies), which is
explained by the use of SP as part of malaria control,
with a strategy termed intermittent preventive
therapy in infants (IPTi) and children (IPTc) (see
Glossary) (Aponte et al. 2009; Gosling et al. 2010).
Other frequently used antimalarials in the paediatric
population identiﬁed through our systematic review
were amodiaquine and artesunate (both 15%) and
chloroquine (10%). Albendazole was the most com-
monly studied anthelminthic drug (5% of all trials).
PK studies
Fifty-seven studies were retrieved after systemati-
cally searching for PK investigations of antiparasitic
drugs in paediatrics covering a period of 10 years and
8 months until the end of August 2010. Forty studies
were excluded when applying our selection criteria
(study participants aged 518 years or studies
including both adults and children (n = 39); one
trial investigated a supplement rather than a drug).
The sample size of the 17 included studies ranged
from as few as 10 individuals to 899 subjects
(Table 1). Two-third of the trials (n = 11) recruited
10 to 50 participants, while only one trial had a
sample size of more than 250 individuals. The most
commonly studied age group were children: 10 trials
were performed exclusively with children and ﬁve
studies included both children and infants. The age
groups of solely infants and adolescents in combi-
nation with children were only represented in a single
study each. PK parameters of antimalarial drugs were
studied in 15 of the 17 trials. The remaining two PK
studies investigated anthelminthics and a neoplastic
agent for leishmaniasis. The antimalarial drugs
artesunate and quinine were investigated most often
(each drug in 29% of the PK studies identiﬁed). With
regard to anthelminthic drugs, albendazole and
praziquantel were the only compounds subjected to
PK investigations in the paediatric population.
DRUG FORMULATIONS
General considerations
Although there is a pressing need for developing new
antiparasitics, very few drugs have been marked-
approved in recent years. For example, while 11 new
antimalarials have been marketed between 2000 and
2009, no new drugs have been approved in any of the
other parasitic disease categories over the same period
(Cohen et al. 2010). Given the paucity of clinical
trials in paediatrics focusing on diseases other than
malaria, it is conceivable that only very few, if any,
drugs for other parasitic diseases will be forthcoming
in the near future. However, drugs can be consider-
ably optimised when new drug formulations are
developed (Kayser et al. 2003).
Desired criteria for drug formulations include
(1) good bioavailability; (2) safe excipients and
ingredients; (3) dose uniformity; (4) ease and safety
of administration; and (5) socio-cultural acceptability
(Breitkreutz and Boos, 2007). Based on factors such
as solubility and taste of the compound formulation,
development can be a time consuming and techni-
cally challenging task and the ﬁnancial implications
are considerable (Milne, 2009). Yet, an acceptable
formulation is particularly important for children.
Indeed, one of the key issues in the development of
paediatric drugs is the selection of the most appro-
priate dosage form in relation to age. Numerous drug
Fig. 3. Geographic location of paediatric drug trials (%)
identiﬁed through a systematic review covering a period
of 10 years and 8 months until the end of August 2010.
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administration routes are available, such as
peroral, nasal, parenteral, topical, rectal or buccal
(Breitkreutz et al. 2007). Matrixes combining diﬀer-
ent paediatric age groups, routes of administration
and dosage forms have therefore been developed
to assist in selecting the ideal formulation (see,
for example, http://www.ema.europa.eu/docs/en_
GB/document_library/Scientiﬁc_guideline/2009/09/
WC500003782.pdf and Breitkreutz (2009)). A
slightly simpliﬁed matrix for oral routes of drug
administration using ‘traﬃc light colours’ is depicted
in Fig. 5. Ideal, recommended and desired dosage
forms are shown using green colour, less preferred
but probable applicable dosage forms are marked
with orange colour and not applicable oral dosage
forms are depicted in red. For example, solid dosage
forms might pose problems to small children as they
have diﬃculties swallowing tablets. It follows that
tablets and capsules are not recommended for infants
and toddlers, and applicable but not preferred for
preschool-aged children.
Clearly, oral drug administration is the predomi-
nant route in paediatric patients and diﬀerent oral
dosage forms (e.g. solutions, syrups, powder, gran-
ules and eﬀervescent tablets) have been developed.
However, in particular when drugs are not licensed
for children (i.e. oﬀ-label use) suitable liquid forms
are often not available. Inert ingredients must be
selected very carefully as children might have adverse
reactions to colourings, ﬂavouring or preservatives,
which are commonly used in adult formulations
(Milne, 2009). Taste is a particularly crucial issue to
ascertain high compliance in children. For example, a
survey carried out in theUS interviewing 500 parents
Antimalarials
Antinematodals
Agents against amoebiasis and
other intestinal protozoal diseases
Antitrematodals
Agents against
leishmaniasis/trypanosomiasis
Key
1.02.9
3.7
9.8
82.6
Fig. 4. Drug classes investigated (%) in a systematic review covering a period of 10 years and 8 months until the end of
August 2010.
Solution/
drops
Emulsion/
suspension
Effervescent
dosage forms
Powders/
multiparticulates
Tablets
Capsules
Orodispersable
dosage forms
Chewable tablets
Dosage form Preterm
newborns
Term
newborn
infants
Infants
and
toddlers
Pre-
school
children
Children Ado-
lescents
Fig. 5. Matrix combining diﬀerent dosage forms for oral routes of drug administration for diﬀerent paediatric
age groups.
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and caretakers has shown that taste was, among two-
third of the children, a reason for non-compliance
(Milne and Bruss, 2008; Milne, 2009).
Anthelminthic drug formulations
Table 2 shows the most important anthelminthic
drugs currently employed within the frame of
preventive chemotherapy programmes, including
the most common formulations (WHO, 2006; Hotez
et al. 2007). Importantly, these anthelminthics have
become the drugs of choice against schistosomiasis,
food-borne trematodiases and soil-transmitted
helminthiases, the latter including strongyloidiasis.
Indeed, millions of people are given one or several of
these drugs each year, particularly school-aged
Table 2. Available drug formulations, their producers, recommended dosages and paediatric use for drugs
used for the treatment of schistosomiasis, food-borne trematodiases, soil-transmitted helminthiases
and strongyloidiasis
Infection Drug Formulation Producer(s) Recommended dosage Paediatric use
Schistosomiasis
and food-borne
trematodiases
Praziquantel Tablet,
600mg
Four large scale
producers: Merck,
Shin Poong,
EIPICO, Cipla
40mg/kg once
(schistosomiasis),
multiple doses
(schedule depending
on trematode; food-
borne trematodiases)
Experience in
children
below 4 years
is limited
Praziquantel Syrup,
120mg/ml
(Epiquantel)
EIPICO
Fascioliasis Triclabendazole Tablet,
250mg
Novartis 10mg/kg once (20mg/
kg in the case of
treatment failures)
No experience
in children
below 6 years
Soil-transmitted
helminthiases
Albendazole Chewable
tablet, 200
and 400mg
GlaxoSmithKline,
many generic
producers
400mg once for
individuals aged
2 years and above,
single 200mg once
for individuals aged
1–2 years
No experience
in children
below 1 year
Suspension,
100mg/5ml
20ml once for
individuals aged
2 years and above,
10ml once for
individuals aged
1–2 years
Mebendazole Chewable
tablet, 100
and 500mg
Janssen
Pharmaceutica,
many generic
producers
500mg once, 100mg
twice a day for 3 days
No experience
in children
below 1 year
Suspension,
100mg/5ml
25ml once, 5 ml twice a
day for 3 days
Levamisole Tablet, 50 and
150mg
ICI.
Pharmaceuticals,
many generic
producers
2·5 mg/kg once No experience
in children
below 1 year
Suspension,
40mg/5ml
Generic producers (e.
g. EIPICO)
2·5 mg/kg once
Pyrantel pamoate Chewable
tablet,
250mg
Pﬁzer 10mg/kg once, 10mg/
kg for 3 days for
individuals aged 1 year
and above
No experience
in children
below 1 year
Suspension,
50mg/ml
Pﬁzer 1ml for every 5 kg
of body weight
Strongyloidiasis Ivermectin Tablet, 3 and
6mg
200 μg/kg single dose
15 kg and above
Safety and
eﬃcacy in
individuals
weighing less
than 15 kg
have not been
established
Albendazole See above See above Multiple doses
(e.g. 400mg twice
daily for 3 days) ages
2 years and above
See above
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children (WHO, 2008b, 2010b,c; Fenwick et al. 2009).
Manufacturers and recommended dosages, both for
adults and the paediatric population are presented. In
the remainder of this section we highlight short-
comings linked to drug formulations available for
major helminthiases, such as dosing accuracy, lack of
PK investigations, unknown bioavailability for ex-
temporaneous preparation and indeed lack of suitable
formulations for small children.
Praziquantel
In 2008, 17·5 million individuals were treated with
praziquantel in the frame of preventive chemother-
apy programmes against schistosomiasis (WHO,
2010b). It is conceivable that several more million
people were administered praziquantel, facilitated by
local, regional and national control eﬀorts, purchase
from pharmaceutical stores, distributed by non-
governmental organisations and aid workers, but
these data were not reported to WHO. However, tens
of millions of individuals, particularly school-aged
children at-risk of schistosomiasis in Africa, still lack
access to praziquantel (Utzinger et al. 2009; Hotez
et al. 2010; WHO, 2010b). There is a paucity of data
regarding the number of people at risk of food-borne
trematodiases who have been treated with praziquan-
tel in the frame of preventive chemotherapy.
At present, praziquantel is recommended for
individuals aged 4 years and above (WHO, 2002a;
Biltricide, package insert). Praziquantel tablets
(600 mg) are large, bitter in taste and the rec-
ommended dosage for preventive chemotherapy is
40mg/kg, administered in a single oral dose (Hotez
et al. 2007; Meyer et al. 2009). Praziquantel tablets
are often split into two or even four parts. However, it
has been shown that the weight of split tablets ranges
from 50–150% of the desired weight of the half-tablet
weight and even the use of tablet cutters do not
improve accuracy (Standing and Tuleu, 2005).
Furthermore, although crushing of praziquantel
tablets has been recommended by the manufacturer
(package leaﬂet; http://www.merck.com), and indeed
employed in recent studies with preschool-aged
children infected with schistosomes (Odogwu et al.
2006; Betson et al. 2010; Garba et al. 2010), the
bioavailability of the crushed formulation might
diﬀer from the original tablet form. To our knowl-
edge, the bioequivalence of praziquantel adminis-
tered as crushed tablets versus tablets swallowed
as a whole remains to be investigated. For example,
a recent study, which compared PK parameters of
telithromycin administered either as whole tablets or
crushed (and oﬀered with nutritional supplement
drink) found that both methods of administration
were bioequivalent. Hence, crushing of telithromy-
cin could be a viable method of administration for
patients unable to swallow whole tablets (Lippert
et al. 2005). However, it should be kept in mind that
it is diﬃcult to mask the bitter taste of crushed
tablets. Infants and children react unfavourably to
bitter tastes and the more bitter the drug, the more
likely it will be rejected (Mennella and Beauchamp,
2008; Schwartz et al. 2009). Since praziquantel is
marketed as racemate, and the antischistosomal
activity is stereoselective, new eﬀorts are underway
to develop a low-cost chemical synthesis for the active
enantiomer, L-praziquantel (Meyer et al. 2009). Of
note, L-praziquantel is less bitter than racemic
praziquantel (Meyer et al. 2009) and one study in
the People’s Republic of China reported less adverse
events of L-praziquantel compared to the racemate
(Wu et al. 1991).
A praziquantel syrup formulation is available
(Doenhoﬀ et al. 2009). However, it is not commonly
used and not knownwhether bioequivalence has been
thoroughly studied. In addition, it is not known
which excipients, which are required for dose
uniformity, stability or taste (Standing and Tuleu,
2005) are present. A detailed summary of excipients,
their technological function and adverse events has
been provided by Piﬀeri and Restani (2003).
Finally, there is a need to study the safety, dose-
response and PK of praziquantel thoroughly in
children below the age of 4 years, because recent
studies in diﬀerent epidemiological studies docu-
mented that schistosomiasis can occur in infants and
preschool-aged children, hence well before the age
of 4 years (Maﬁana et al. 2003; Bosompem et al.
2004; Odogwu et al. 2006; Stothard and Gabrielli,
2007; Betson et al. 2010; Garba et al. 2010; Sousa-
Figueiredo et al. 2010b; Stothard et al. 2011).
Preschool-aged children are presently not targeted
in schistosomiasis preventive chemotherapy cam-
paigns. However, it has been emphasised that pre-
school children do not only play a role in local disease
transmission, but importantly active infections ac-
quired at early ages might aggravate the clinical
signiﬁcance of the disease in later-life (see Stothard
et al. in this special issue). First trials have been
carried out, treating preschool children with half or
three quarters of a tablet depending on height, using
an extended dose pole (Sousa-Figueiredo et al.
2010a,b). However, as highlighted in the present
manuscript, a century ago it was recognised by
Dr. Jacobi that children and infants are not miniature
men and women requiring just reduced doses
(Kearns et al. 2003). Rather than using an empirical
approach and applying weight-based calculations to
the adult dose, there is a need for in-depth studies
with praziquantel, including PK, to determine the
proper formulations and doses in paediatric patients.
Triclabendazole
Similar to praziquantel, triclabendazole is currently
not registered for use in young children (<6 years of
age), but oﬀ-label use in this age group has been
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reported (WHO, 2007b). Triclabendazole is the
current drug of choice against fascioliasis (Keiser
et al. 2005; Fairweather, 2009; Keiser and Utzinger,
2010) and we strongly recommend that available
data of the safety and eﬃcacy of triclabendazole in
preschool-aged children be scrutinized. We antici-
pate that the evidence-base is currently insuﬃcient,
and hence additional clinical trials are warranted to
ﬁll existing gaps. Furthermore, an appropriate
triclabendazole formulation for young children
might be considered. However, it is unlikely that
progress in this ﬁeld will be made in the near future
given the fact that fascioliasis is one of the most
neglected tropical disease and triclabendazole is
currently registered in only four countries (Keiser
et al. 2005).
Albendazole, mebendazole, levamisole and
pyrantel pamoate
The main drugs used for the treatment of soil-
transmitted helminthiases are albendazole, meben-
dazole, levamisole and pyrantel pamoate (Bethony
et al. 2006; Keiser and Utzinger, 2008). Clearly, the
former two – the benzimidazoles albendazole and
mebendazole – are the most widely used drugs within
the frame of preventive chemotherapy campaigns
(WHO, 2006; Hotez et al. 2007). At the moment
all four drugs are recommended for children aged
12months and above. There are currently insuﬃcient
data on safety and eﬃcacy for use in younger children
which is a problem, as infections are often acquired
by infants before they reach 12 months (WHO,
2002a; Montresor et al. 2003). It is interesting to note
that for the two widely used benzimidazoles no age-
speciﬁc dosing regimens exist. For example, a 1-year-
old child (approximately 10 kg) receives the same
500mg mebendazole dose than an 80 kg adult.
Indeed, dosage adaptations based on weight or
body surface area (Kearns et al. 2003) have not been
suggested for the benzimidazoles in children. To our
knowledge PK studies with these drugs have neither
been undertaken in infants nor in children. We and
others have highlighted that the majority of anthel-
minthics currently used for preventive chemotherapy
have been developed in veterinary parasitology, and
hence were not suﬃciently optimised for treating
human helminth infections (Geary et al. 2010; Keiser
and Utzinger, 2010).
Albendazole, mebendazole, levamisole and pyran-
tel pamoate are available as liquid formulations,
which are obviously most appropriate for paediatric
patients (Table 2). Typical target dose volumes for
paediatric liquid formulations are <5ml for children
under the age of 5 years and <10ml for children aged
5 years and above (European Medicines Agency,
2006). However, themore pleasant the formulation of
the medicinal product tastes, the higher the dose
volume which will be tolerated by the child. For
example, 20ml of an albendazole suspension are
required to achieve a total dose of 400mg. However,
in large-scale drug administration programmes liq-
uid formulations of albendazole, mebendazole or
levamisole and pyrantel pamoate are rarely used.
Albendazole, mebendazole and pyrantel pamoate are
also available as chewable tablets. Although the use
of chewable tablets is oﬃcially recommended for
children aged above 6 years, a systematic review on
the safety of chewable tablets for children in the US
concluded that chewable tablets were a safe and well
tolerated alternative to traditional paediatric formu-
lations (Michele et al. 2002). Tragically, in 2007 in
Ethiopia four children below the age of 3 years died
from choking on chewable albendazole tablets during
a deworming campaign (WHO, 2007a). Reasons for
the widespread use of tablets in preventive che-
motherapy campaigns are the higher cost of the
suspension compared to tablets, diﬃculties of trans-
port and storage due to the larger volume of the liquid
formulation, stability issues and the diﬃculties in
handling the liquid formulation. Hence, additional
resources for implementation of liquid formulations
would be required. Moreover, medication errors
commonly occur with liquid formulations. It has
been shown, for example that poor dose uniformity
is achieved using spoons and dosing cups, hence
dropper tubes or syringes are recommended
(Breitkreutz and Boos, 2007).
Ivermectin
Ivermectin, the current drug of choice for strongy-
loidiasis, is marketed as 3mg and 6mg scored tablets.
Ivermectin was approved for human use in 1988 and
is widely used to control and eliminate ﬁlarial
infections, usually in combination with albendazole
(Fox, 2006; Taylor et al. 2010). Ivermectin is labelled
for children weighting more than 15 kg, since the
drug might cross the poorly-developed blood brain
barrier in infants resulting in possible neurotoxic
events (Fox, 2006). There is a need to study the safety
of ivermectin in infants in greater detail. In addition,
to our knowledge, liquid formulations are not
available, hence preschool-aged children, are routi-
nely treated with tablets, which is not the preferred
dosage form for this age group (European Medicines
Agency, 2006).
IMPLICATIONS FOR CONTROL
In the mid-1980s, a paradigm shift occurred in the
global strategy against schistosomiasis and other
major helminth infections; i.e. transmission control
was gradually replaced by morbidity control. The
advent of safe anthelminthic drugs that showed high
eﬃcacy at single oral doses, both in terms of cure
rate and egg reduction rate, and hence morbidity
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reduction, was at the root of this shift (WHO, 1985).
Once the price of anthelminthics plummeted (e.g.
terming out of patents or pharmaceutical companies
providing anthelminthic drugs free of charge),
repeated large-scale administration to at-risk popu-
lations became feasible. In May 2001, World Health
Assembly (WHA) resolution 54·19 was endorsed,
urging member states to regularly treat at least 75%
of school-aged children at risk of schistosomiasis
and soil-transmitted helminthiases with praziquantel
and albendazole/mebendazole, respectively (WHO,
2002b). Major progress has been made over the past
decade and, in 2006, the ﬁrst African countries
reached the 75% target of administering benzimi-
dazoles to school-aged children at risk of soil-
transmitted helminthiasis (WHO, 2008b, 2010c;
Savioli et al. 2009).
With regard to schistosomiasis, however, only half
a dozen countries in sub-Saharan Africa have (re-)
established national schistosomiasis control pro-
grammes (Fenwick et al. 2009). Hence only a small
fraction of school-aged children at-risk of morbidity
due to schistosomiasis are regularly given praziquan-
tel (Hotez et al. 2010; WHO, 2010b). In view of
recent reports from diﬀerent epidemiological settings
documenting S. haematobium and S. mansoni single
and even mixed species infections among preschool-
aged children (Maﬁana et al. 2003; Bosompem et al.
2004; Odogwu et al. 2006; Stothard and Gabrielli,
2007; Betson et al. 2010; Garba et al. 2010; Sousa-
Figueiredo et al. 2010b; Stothard et al. 2011), the
question has arisen whether preventive chemother-
apy should be extended to this age group.
We welcome this discussion and an informal
consultation held at WHO headquarters in Geneva
in September 2010. We oﬀer the following points for
consideration, with Fig. 6 serving as a conceptual
framework. Fig. 6A depicts a typical age-prevalence
curve of schistosomiasis, clearly documenting that
school-aged children are at highest risk of egg-patent
infection and high infection intensity (Jordan and
Webbe, 1969). Let us ﬁrst focus on school-aged
children (age: 5–19 years). The mean prevalence in
this age group, based on detection of S. mansoni eggs
in stool samples, is approximately 40%. Concur-
rently, the egg-patent prevalence of S. mansoni in
preschool-aged children (age: 0–4 years) is approxi-
mately 10% or one-fourth of their older counterparts.
Of note, immunodiagnostic markers, particularly
antigens in urine, can be detected earlier than eggs
in stool, and hence the respective prevalence based on
antigens might be higher than that determined by egg
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Fig. 6. Conceptual framework summarising the age-prevalence curve of schistosomiasis (a) and hypothetical scenarios of
S. mansoni-hookworm co-infection in highly endemic (b) and low endemic (c) settings.
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patency (Stothard et al. 2011). Notwithstanding the
shortcoming of egg patency at early age, let us assume
a similar age-pattern of S. mansoni and hookworm
infection.
Fig. 6B shows three hypothetical scenarios with
school-aged children at risk of a S. mansoni infection,
a hookworm infection, and a S. mansoni-hookworm
co-infection. In an epidemiological setting where
both infections are highly endemic and no control
measures in place, i.e. 80% of school-aged children
infected with either parasite, the likelihood of a co-
infection is 64% under the assumption of random
parasite distribution. We argue that such settings are
rare to ﬁnd in contemporary Africa. Suppose that
control eﬀorts have been launched and infection
prevalences dropped by 50% for each parasite. The
likelihood of a co-infection has now been reduced to
16%. Concurrently, 36% of the school-aged children
are free of both S. mansoni and hookworm infection.
Now, let us suppose that preventive chemotherapy is
continued and the prevalence of either parasite
infection further reduced to 20% each (Fig. 6C).
The likelihood of a co-infection has further dropped
to 4%, whereas two-third of the school-aged children
are helminth-free. Next, let us focus on preschool-
aged children where the prevalence of each parasite
is one-fourth of the prevalence in their older
counterparts. In the latter setting, less than 1% of
preschool-aged children are co-infected, whereas
more than 90% show no infection at all. Can
preventive chemotherapy, using both praziquantel
and a benzimidazole, which have yet to be properly
tested in children below the age of 4 years, be justiﬁed
in such a setting? There is a pressing need for
additional studies, including risk-beneﬁt analyses.
For example, the risk of not treating the preschool-
aged population in terms of potential morbidity
should be determined and compared to the risk of
administering two drugs that lack child-friendly
formulations, and detailed information on eﬃcacy,
safety and PK in this age group. We conjecture that
new research is urgently required to resolve these
issues before extension of preventive chemotherapy
to preschool-aged children.
CONCLUDING REMARKS AND RESEARCH NEEDS
Infectious diseases continue to be a leading cause of
morbidity and mortality in children, particularly in
low-income countries. As we have shown, there is a
paucity of studies assessing the safety and eﬃcacy of
antiparasitic drugs in children. Moreover, PK inves-
tigations and studies in infants and adolescents with
antiparasitics are a totally neglected research area.
Though sometimes diﬃcult to put into practice, PK
studies should also assess the impact of the parasitic
infection on the disposition kinetics of the drug,
hence ideally be carried out in healthy and diseased
children. For example, it has been demonstrated that
PK parameters were altered in patients infected with
the liver ﬂuke Opisthorchis viverrini (Na Bangchang
et al. 1993). Similarly, in many disease areas no
progress has been made with tailored drug formu-
lations for children. Hence, oﬀ-label use, empirical
dose adaptations and formulation tampering are still
the rule rather than the exception.
The forging of new alliances and public-private
partnerships between academia, pharmaceutical
companies and philanthropic organisations (e.g. Bill
& Melinda Gates Foundation) hold promise to ﬁll
the current gaps for optimising current antiparasitic
drugs and developing the next generation of anti-
parasitic drugs (Moran, 2005; Nwaka and Hudson,
2006; Keiser and Utzinger, 2007; Moran et al.
2009). The Medicines for Malaria Venture (MMV)
and the Drugs for Neglected Disease initiative
(DNDi) can serve as useful role models (see
Glossary).
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GLOSSARY
ADMET: Absorption, distribution, metabolism,
excretion and toxicity
ATC: Anatomical Therapeutical Chemical classiﬁ-
cation system
BPCA: Best Pharmaceuticals for Children Act (2002)
DALY: Disability-adjusted life year is a composite
measure to estimate the burden of disease or injury,
expressed as the number of years lost due to ill-
health, disability or premature death
DNDi: Drugs for Neglected Diseases initiative is a
collaborative, not-for-proﬁt drug research and
development organisation founded in 2003, based
in Geneva, Switzerland that aims to improve the
quality of life and the health of people suﬀering
from neglected diseases by using an alternative
model to develop drugs for these diseases and by
ensuring equitable access to new and ﬁeld-relevant
health tools (http://www.dndi.org/)
FDA: US Food and Drug Administration (http://
www.fda.gov)
FDAMA: FDA Modernization Act (1998)
IPT: Intermittent preventive therapy is a public
health intervention aimed at treating and pre-
venting malaria episodes in infants (IPTi), children
(IPTc) and pregnant women (IPTp). The inter-
vention builds on two tested malaria control
strategies, namely (1) to clear existing parasites
(treatment eﬀect seen inmass drug administrations)
and (2) to prevent new infections (prophylaxis)
MMV: Medicines for Malaria Venture is a not-for-
proﬁt public-private partnership established in
1999, based in Geneva, Switzerland that aims to
reduce the burden of malaria in disease-endemic
countries by discovering, developing and facilitat-
ing delivery of new, eﬀective and aﬀordable anti-
malarial drugs (http://www.mmv.org/)
Oﬀ-label: Use for this population/age class not
mentioned in the label
Preventive (anthelminthic) chemotherapy:Use
of (anthelminthic) drugs, either alone or in combi-
nation, as a public health tool against (helminth)
infections
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